These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

230 related items for PubMed ID: 30726549

  • 21. Cost-effectiveness of ranibizumab and aflibercept to treat diabetic macular edema from a US perspective: analysis of 2-year Protocol T data.
    Holekamp N, Duff SB, Rajput Y, Garmo V.
    J Med Econ; 2020 Mar; 23(3):287-296. PubMed ID: 31502893
    [Abstract] [Full Text] [Related]

  • 22. Cost-effectiveness of bevacizumab and ranibizumab for newly diagnosed neovascular macular degeneration.
    Stein JD, Newman-Casey PA, Mrinalini T, Lee PP, Hutton DW.
    Ophthalmology; 2014 Apr; 121(4):936-45. PubMed ID: 24405740
    [Abstract] [Full Text] [Related]

  • 23. Cost-effectiveness of ranibizumab and bevacizumab for age-related macular degeneration: 2-year findings from the IVAN randomised trial.
    Dakin HA, Wordsworth S, Rogers CA, Abangma G, Raftery J, Harding SP, Lotery AJ, Downes SM, Chakravarthy U, Reeves BC, IVAN Study Investigators.
    BMJ Open; 2014 Jul 29; 4(7):e005094. PubMed ID: 25079928
    [Abstract] [Full Text] [Related]

  • 24. A United Kingdom-based economic evaluation of ranibizumab for patients with retinal vein occlusion (RVO).
    Taylor M, Serbetci E, Ferreira A, Gairy K, Lewis L, Blouin J, Mitchell P.
    J Med Econ; 2014 Jun 29; 17(6):423-34. PubMed ID: 24673384
    [Abstract] [Full Text] [Related]

  • 25. Cost-effectiveness of ranibizumab in the treatment of visual impairment due to diabetic macular edema.
    Haig J, Barbeau M, Ferreira A.
    J Med Econ; 2016 Jul 29; 19(7):663-71. PubMed ID: 26882365
    [Abstract] [Full Text] [Related]

  • 26. Computerized model of cost-utility analysis for treatment of age-related macular degeneration.
    Fletcher EC, Lade RJ, Adewoyin T, Chong NV.
    Ophthalmology; 2008 Dec 29; 115(12):2192-8. PubMed ID: 18930556
    [Abstract] [Full Text] [Related]

  • 27. A Retrospective Study of Ranibizumab Treatment Regimens for Neovascular Age-Related Macular Degeneration (nAMD) in Australia and the United Kingdom.
    Johnston RL, Carius HJ, Skelly A, Ferreira A, Milnes F, Mitchell P.
    Adv Ther; 2017 Mar 29; 34(3):703-712. PubMed ID: 28144918
    [Abstract] [Full Text] [Related]

  • 28. Clinical Efficacy and Safety of Current Interventions for Choroidal Neovascularization Associated with Rare Diseases: A Systematic Literature Review.
    Bennett N, John L, Likhar N, Agrawal R, Amoaku WM.
    Adv Ther; 2018 May 29; 35(5):591-603. PubMed ID: 29687336
    [Abstract] [Full Text] [Related]

  • 29. The cost-effectiveness of photodynamic therapy for fellow eyes with subfoveal choroidal neovascularization secondary to age-related macular degeneration.
    Sharma S, Brown GC, Brown MM, Hollands H, Shah GK.
    Ophthalmology; 2001 Nov 29; 108(11):2051-9. PubMed ID: 11713079
    [Abstract] [Full Text] [Related]

  • 30. Cost-effectiveness of treating wet age-related macular degeneration at the Kuopio University Hospital in Finland based on a two-eye Markov transition model.
    Vottonen P, Kankaanpää E.
    Acta Ophthalmol; 2016 Nov 29; 94(7):652-656. PubMed ID: 27481048
    [Abstract] [Full Text] [Related]

  • 31. Ranibizumab and pegaptanib for the treatment of age-related macular degeneration: a systematic review and economic evaluation.
    Colquitt JL, Jones J, Tan SC, Takeda A, Clegg AJ, Price A.
    Health Technol Assess; 2008 May 29; 12(16):iii-iv, ix-201. PubMed ID: 18462575
    [Abstract] [Full Text] [Related]

  • 32. Cost effectiveness of pegaptanib for the treatment of age-related macular degeneration in the UK.
    Wolowacz SE, Roskell N, Kelly S, Maciver FM, Brand CS.
    Pharmacoeconomics; 2007 May 29; 25(10):863-79. PubMed ID: 17887807
    [Abstract] [Full Text] [Related]

  • 33. Choroidal Thickness Changes After Intravitreal Ranibizumab for Exudative Age-Related Macular Degeneration.
    Minnella AM, Federici M, Falsini B, Barbano L, Gambini G, Lanza A, Caporossi A, Savastano MC.
    BioDrugs; 2016 Aug 29; 30(4):353-9. PubMed ID: 27189458
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Ranibizumab for myopic choroidal neovascularization.
    Ng DSC, Fung NSK, Yip FLT, Lai TYY.
    Expert Opin Biol Ther; 2020 Dec 29; 20(12):1385-1393. PubMed ID: 33003962
    [Abstract] [Full Text] [Related]

  • 37. Cost Evaluation of Panretinal Photocoagulation versus Intravitreal Ranibizumab for Proliferative Diabetic Retinopathy.
    Lin J, Chang JS, Smiddy WE.
    Ophthalmology; 2016 Sep 29; 123(9):1912-8. PubMed ID: 27425822
    [Abstract] [Full Text] [Related]

  • 38. Cost-effectiveness of intravitreal aflibercept versus other treatments for wet age-related macular degeneration in Japan.
    Yanagi Y, Fukuda A, Barzey V, Adachi K.
    J Med Econ; 2017 Feb 29; 20(2):204-212. PubMed ID: 27701921
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 12.